What is tumor-infiltrating lymphocyte (TIL) therapy for Prostate Cancer

Understanding Tumor-Infiltrating Lymphocyte (TIL) Therapy for Prostate Cancer

I appreciate this question because it touches on an emerging area of prostate cancer research—though I should be upfront: TIL therapy is NOT yet an established treatment for prostate cancer patients. Let me explain what's happening in the research and why prostate cancer presents unique challenges.

What Are TILs (Tumor-Infiltrating Lymphocytes)?

TILs are immune cells—specifically T-cells—that naturally accumulate inside tumors. Think of them as your body's soldiers that have already found the cancer battlefield. The key type is cytotoxic T-lymphocytes (CTLs), which are the cells trained to kill cancer cells.

According to the CancerPatientLab webinar on immunotherapy, pathologists grade TILs in three categories:

• Absent - no immune cells present
• Non-brisk - some immune cells, but scattered
• Brisk - dense infiltration of immune cells actively surrounding and killing cancer cells

Why Prostate Cancer Is Different (The Cold Tumor Problem)

Here's the critical issue: Most prostate cancers are "cold tumors" with very few TILs present.

According to Dr. [removed] Subudhi's research presented in the CancerPatientLab webinars:

"One of the problems with prostate cancer is that there are very few T-cells present... If this was melanoma or lung cancer, most of this would be covered in brown staining [indicating T-cells]. But in prostate cancer, there are just very few there."

In fact, a small case series of three advanced prostate cancer patients showed that all three had absent or very few TILs—a striking finding that suggests prostate cancer naturally resists immune infiltration.

The Current State of TIL Therapy for Prostate Cancer

TIL therapy has NOT been developed as a clinical treatment for prostate cancer yet. Here's why:

1. Lack of Research Data: According to the webinars, while TIL assessment and scoring methods exist for melanoma (where they've been successful), there is currently no comparable research showing TIL distribution patterns in metastatic castrate-resistant prostate cancer (mCRPC).

2. The Tumor Microenvironment Challenge: Prostate tumors have a hostile immune environment with:

   • Very few good immune cells (CTLs)
   • Many bad immune cells called suppressive myeloid cells that actively shut down the immune response
   • An inverse relationship: the more myeloid suppressor cells present, the fewer T-cells are found

3. Bone Metastases Complicate Things: Since 70-80% of men with metastatic prostate cancer have bone metastases, and these show even fewer T-cells than soft tissue tumors, this is a major barrier.

What IS Being Done Instead: Making Prostate Cancer "Hot"

Rather than harvesting existing TILs (which are scarce), researchers are focusing on strategies to drive T-cells INTO prostate tumors:

Current approaches include:

• Vaccines (like Provenge/sipuleucel-T, FDA-approved since 2010) - train the immune system to attack prostate cancer
• Immune checkpoint inhibitors (like ipilimumab/Yervoy targeting CTLA-4) - remove the "brakes" on T-cells so they can attack
• T-cell bispecific antibodies - act like bridges connecting T-cells directly to cancer cells
• Combination approaches - pairing immunotherapies with radiation or other drugs to enhance immune response

The Future Direction

According to Dr. [removed] Rech in the CancerPatientLab webinars, researchers are investigating how to improve the tumor microenvironment by targeting the molecular factors that keep prostate cancer "cold." This includes research into:

• Blocking tumor necrosis factor (TNF) to reduce immunosuppression
• Transforming bad myeloid cells into good ones
• Using personalized neoepitope vaccines combined with immune-modulating drugs

Questions to Ask Your Oncologist

If you're interested in immunotherapy approaches for prostate cancer:

1. Has my tumor been tested for MSI (microsatellite instability) or mismatch repair deficiency? - This helps identify which patients might respond to checkpoint inhibitors
2. What immunotherapy clinical trials am I eligible for? - T-cell bispecifics and combination approaches are actively being studied
3. Could my treatment include a vaccine approach combined with checkpoint inhibitors? - This combination strategy is showing promise
4. What biomarker testing (like BostonGene's immune profiling) could help predict my response to immunotherapy?

Bottom Line

TIL therapy as a standalone treatment doesn't yet exist for prostate cancer because prostate tumors naturally have very few TILs. However, the field is actively working on strategies to convert "cold" prostate tumors into "hot" ones by driving T-cells into the tumor and removing the immune brakes that keep them out. This is an active area of clinical research with several promising approaches in development.

---

Sources cited:

• CancerPatientLab Webinar: "Update on Immunotherapies for Metastatic Castrate Resistant Prostate Cancer" (Sumit Subudhi)
• CancerPatientLab Webinar: "Immunotherapy in Prostate Cancer - CAR-T and the Tumor Microenvironment" (Andrew Rech)
• CancerPatientLab Webinar: "How MSI and Other Tests Can Guide Immunotherapies for Cancer Treatment" (Heather Tomlinson)

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.